These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 31704972)

  • 1. CDK2-mediated site-specific phosphorylation of EZH2 drives and maintains triple-negative breast cancer.
    Nie L; Wei Y; Zhang F; Hsu YH; Chan LC; Xia W; Ke B; Zhu C; Deng R; Tang J; Yao J; Chu YY; Zhao X; Han Y; Hou J; Huo L; Ko HW; Lin WC; Yamaguchi H; Hsu JM; Yang Y; Pan DN; Hsu JL; Kleer CG; Davidson NE; Hortobagyi GN; Hung MC
    Nat Commun; 2019 Nov; 10(1):5114. PubMed ID: 31704972
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of CDK2 reduces EZH2 phosphorylation and reactivates ERα expression in high-grade serous ovarian carcinoma.
    Han Y; Wei Y; Yao J; Chu YY; Li CW; Hsu JL; Nie L; Hung MC
    Am J Cancer Res; 2020; 10(4):1194-1206. PubMed ID: 32368395
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phosphorylation of EZH2 at T416 by CDK2 contributes to the malignancy of triple negative breast cancers.
    Yang CC; LaBaff A; Wei Y; Nie L; Xia W; Huo L; Yamaguchi H; Hsu YH; Hsu JL; Liu D; Lang J; Du Y; Lien HC; Li LY; Deng R; Chan LC; Yao J; Kleer CG; Hortobagyi GN; Hung MC
    Am J Transl Res; 2015; 7(6):1009-20. PubMed ID: 26279746
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epigenetic Co-Deregulation of EZH2/TET1 is a Senescence-Countering, Actionable Vulnerability in Triple-Negative Breast Cancer.
    Yu Y; Qi J; Xiong J; Jiang L; Cui D; He J; Chen P; Li L; Wu C; Ma T; Shao S; Wang J; Yu D; Zhou B; Huang D; Schmitt CA; Tao R
    Theranostics; 2019; 9(3):761-777. PubMed ID: 30809307
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of cyclin dependent kinase 9 by dinaciclib suppresses cyclin B1 expression and tumor growth in triple negative breast cancer.
    Rajput S; Khera N; Guo Z; Hoog J; Li S; Ma CX
    Oncotarget; 2016 Aug; 7(35):56864-56875. PubMed ID: 27486754
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The WNT10B Network Is Associated with Survival and Metastases in Chemoresistant Triple-Negative Breast Cancer.
    El Ayachi I; Fatima I; Wend P; Alva-Ornelas JA; Runke S; Kuenzinger WL; Silva J; Silva W; Gray JK; Lehr S; Barch HC; Krutilina RI; White AC; Cardiff R; Yee LD; Yang L; O'Regan RM; Lowry WE; Seagroves TN; Seewaldt V; Krum SA; Miranda-Carboni GA
    Cancer Res; 2019 Mar; 79(5):982-993. PubMed ID: 30563890
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cyclin E Overexpression Sensitizes Triple-Negative Breast Cancer to Wee1 Kinase Inhibition.
    Chen X; Low KH; Alexander A; Jiang Y; Karakas C; Hess KR; Carey JPW; Bui TN; Vijayaraghavan S; Evans KW; Yi M; Ellis DC; Cheung KL; Ellis IO; Fu S; Meric-Bernstam F; Hunt KK; Keyomarsi K
    Clin Cancer Res; 2018 Dec; 24(24):6594-6610. PubMed ID: 30181387
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of EZH2 Catalytic Activity Selectively Targets a Metastatic Subpopulation in Triple-Negative Breast Cancer.
    Yomtoubian S; Lee SB; Verma A; Izzo F; Markowitz G; Choi H; Cerchietti L; Vahdat L; Brown KA; Andreopoulou E; Elemento O; Chang J; Inghirami G; Gao D; Ryu S; Mittal V
    Cell Rep; 2020 Jan; 30(3):755-770.e6. PubMed ID: 31968251
    [TBL] [Abstract][Full Text] [Related]  

  • 9. EZH2 induces the expression of miR-1301 as a negative feedback control mechanism in triple negative breast cancer.
    Wu Q; Chen Z; Zhang G; Zhou W; Peng Y; Liu R; Chen C; Feng J
    Acta Biochim Biophys Sin (Shanghai); 2018 Jul; 50(7):693-700. PubMed ID: 29790898
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combined inhibition of EZH2 and ATM is synthetic lethal in BRCA1-deficient breast cancer.
    Ratz L; Brambillasca C; Bartke L; Huetzen MA; Goergens J; Leidecker O; Jachimowicz RD; van de Ven M; Proost N; Siteur B; de Korte-Grimmerink R; Bouwman P; Pulver EM; de Bruijn R; Isensee J; Hucho T; Pandey G; van Lohuizen M; Mallmann P; Reinhardt HC; Jonkers J; Puppe J
    Breast Cancer Res; 2022 Jun; 24(1):41. PubMed ID: 35715861
    [TBL] [Abstract][Full Text] [Related]  

  • 11. STAT1-deficient mice spontaneously develop estrogen receptor α-positive luminal mammary carcinomas.
    Chan SR; Vermi W; Luo J; Lucini L; Rickert C; Fowler AM; Lonardi S; Arthur C; Young LJ; Levy DE; Welch MJ; Cardiff RD; Schreiber RD
    Breast Cancer Res; 2012 Jan; 14(1):R16. PubMed ID: 22264274
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dual Src Kinase/Pretubulin Inhibitor KX-01, Sensitizes ERα-negative Breast Cancers to Tamoxifen through ERα Reexpression.
    Anbalagan M; Sheng M; Fleischer B; Zhang Y; Gao Y; Hoang V; Matossian M; Burks HE; Burow ME; Collins-Burow BM; Hangauer D; Rowan BG
    Mol Cancer Res; 2017 Nov; 15(11):1491-1502. PubMed ID: 28751463
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Feline mammary basal-like adenocarcinomas: a potential model for human triple-negative breast cancer (TNBC) with basal-like subtype.
    Wiese DA; Thaiwong T; Yuzbasiyan-Gurkan V; Kiupel M
    BMC Cancer; 2013 Sep; 13():403. PubMed ID: 24004841
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumor-Intrinsic Enhancer of Zeste Homolog 2 Controls Immune Cell Infiltration, Tumor Growth, and Lung Metastasis in a Triple-Negative Breast Cancer Model.
    Monterroza L; Parrilla MM; Samaranayake SG; Rivera-Rodriguez DE; Yoon SB; Bommireddy R; Hosten J; Barragan LC; Marcus A; Dobosh BS; Selvaraj P; Tirouvanziam R
    Int J Mol Sci; 2024 May; 25(10):. PubMed ID: 38791429
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interaction of EZH2 and P65 is involved in the arsenic trioxide-induced anti-angiogenesis in human triple-negative breast cancer cells.
    Jiang F; Li Y; Si L; Zhang Z; Li Z
    Cell Biol Toxicol; 2019 Aug; 35(4):361-371. PubMed ID: 30612216
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of Poliovirus Receptor-like 3 Protein as a Prognostic Factor in Triple-Negative Breast Cancer.
    Leone GM; Mangano K; Caponnetto S; Fagone P; Nicoletti F
    Cells; 2024 Aug; 13(15):. PubMed ID: 39120328
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Overexpression of CDCA7 predicts poor prognosis and induces EZH2-mediated progression of triple-negative breast cancer.
    Ye L; Li F; Song Y; Yu D; Xiong Z; Li Y; Shi T; Yuan Z; Lin C; Wu X; Ren L; Li X; Song L
    Int J Cancer; 2018 Nov; 143(10):2602-2613. PubMed ID: 30151890
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Accelerated mammary maturation and differentiation, and delayed MMTVneu-induced tumorigenesis of K303R mutant ERalpha transgenic mice.
    Herynk MH; Lewis MT; Hopp TA; Medina D; Corona-Rodriguez A; Cui Y; Beyer AR; Fuqua SA
    Oncogene; 2009 Sep; 28(36):3177-87. PubMed ID: 19561644
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The histone methyltransferase EZH2 promotes mammary stem and luminal progenitor cell expansion, metastasis and inhibits estrogen receptor-positive cellular differentiation in a model of basal breast cancer.
    Wu J; Crowe DL
    Oncol Rep; 2015 Jul; 34(1):455-60. PubMed ID: 25998860
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Blockade of the epidermal growth factor receptor tyrosine kinase suppresses tumorigenesis in MMTV/Neu + MMTV/TGF-alpha bigenic mice.
    Lenferink AE; Simpson JF; Shawver LK; Coffey RJ; Forbes JT; Arteaga CL
    Proc Natl Acad Sci U S A; 2000 Aug; 97(17):9609-14. PubMed ID: 10931950
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.